surmount-osa trial tirzepatide results Weight Loss and Sleep Apnea Cure: Science & Solutions — WakeWell Zepbound for Sleep Apnea: 2024

Thuc Vinluta 900 khng c s dng trn nhng ngi bnh c d ng hoc phn ng qu mn vi glutathion hoc cc t dc khc cha trong thuc

2.4% placebo) 86.4% of participants lost at least 5% of body weight 69.1% lost at least 10% 50.5% lost at least 15% STEP 3 (Wadden et al., 2021, JAMA ): Combined with intensive behavioral therapy Average weight loss: 16.0% over 68 weeks Demonstrated that lifestyle support amplifies medication effects STEP 5 (Garvey et al., 2022, Nature Medicine ): Two-year duration study Average weight loss: 15.2% maintained over 104 weeks Demonstrated sustained effectiveness with continued use Retatrutide Clinical Trial Results Phase 2 Trial (Jastreboff et al., 2023, NEJM ): 338 adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities Multiple dose groups (1 mg, 4 mg, 8 mg, 12 mg weekly) Results at the 12 mg dose: Average weight loss: 24.2% in 48 weeks 100% of participants lost at least 5% of body weight 93% lost at least 10% 83% lost at least 15% 63% lost at least 20% Weight loss trajectory had not plateaued at study end Comprehensive Comparison Table Side Effects Comparison Both medications share similar gastrointestinal side effect profiles because they both activate GLP-1 receptors

Can persist longer than nausea or diarrhea

They found the fatigue, nausea, vomiting, headaches joint pain and swelling intolerable

thus, transoral outlet reduction aims to reduce the size of the anastomosis via endoscopic suturing